No Detail Found!

Response of Tocilizumab in Treating Severe to Critical COVID-19; Single-Centre Experience at a Tertiary Care Centre

Author(s)
Sarfraz Khan THQ Hospital Doger, Pakistan,
Malik Muhammad Atif Mayo Hospital,Lahore,Pakistan
Sadia Asif Mayo Hospital,Lahore,Pakistan
Uzma Malik Mayo Hospital,Lahore,Pakistan
Sarmad Zahoor Mayo Hospital,Lahore,Pakistan
Samar Firdous Mayo Hospital,Lahore,Pakistan
Abstract
Objective: To study the effectiveness of Tocilizumab in reducing mortality in severely or critically ill patients. Study Design: Quasi-experimental study Place and Duration of Study: Mayo Hospital, Lahore Pakistan, from Dec 2020 to May 2021. Methodology: The participants meeting the inclusion criteria of the study were allocated to an Experimental and a Control Arm based on age and oxygen requirements. The Experimental-Group was given Tocilizumab plus standard care, while the Control- Group received standard care only. Primary outcome was death, while secondary outcomes were the need for invasive ventilation and length of hospital stay. Results were analyzed after 28 days. Results: Among 81 patients, 60(74.1%) were males, 21(25.9%) were females. Of these, 44(54.3) received Tocilizumab plus Standard Care, while 37(45.7%) received Standard Care only. Out of 44 patients from the Tocilizumab-Group, 21(47.7%) survived, whereas, from 37 in the Standard Care-Group, 15(40.54%) survived at the end of 28 days. However, the difference in survival distributions between the two groups was not statistically significant (p=0.41). Conclusion: Tocilizumab was found to have no significant impact on improving the chances of survival and reducing the risk of Invasive Ventilation in COVID-19 patients. A wider confidence interval, however, cannot rule out the possibility of some benefit or harm. Hence, further studies are needed on this subject.
Publication Details
Page(s) 1468-1471
Published Journal: Pakistan Armed Forces Medical Journal, Volume: 73, Issue: 5, Year: 2023

Request the full text from PASTIC

Keywords
Survival, efficacy, Tocilizumab, standard care, Severe COVID-19
0

Citations

0

Downloads

48

Views